← Eichor
Study identifier: NCT07202897 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.

Condition: Hypertrophic Cardiomyopathy (HCM)  ·  Sponsor: Rennes University Hospital

PhasePhase 3
Planned participants532
Who can joinAll sexes, 40 Years to 80 Years
Healthy volunteersNo

About this study

Hypertrophic cardiomyopathy (HCM) is a common (\> 1/500 in the general adult population) genetically transmitted disease impacting markedly patients' lives from the early ages to the latest. The phenotype as the prognosis of HCM may greatly differ from one patient to another: most patients present no or few symptoms and a near-normal lifespan, while others are severely symptomatic. Paroxysmal, persistent or permanent atrial fibrillation (AF) is frequent in HCM, occurring in more than 20%-25% of patients and is often considered as an important turning point for the quality of life of these patients. AF decreases cardiac output and exercise tolerance, increases hospitalization rate, and markedly increase the risk of embolic stroke with the need for life-anticoagulation. It has been shown that stroke may precede AF discovery and that it may occur at young ages with devastation consequences. AF also may trigger sudden cardiac death. Observational studies have been conducted to search for parameters which correlate with the risk of AF (P wave duration and supra-ventricular burst on the Holter-ECG monitoring, L-wave morphology, degree of hypertrophy, clinical parameters-comorbidities, and size of the left atrium) with no real impact on clinical management. Left Atrial strain (LA-strain) has been recently demonstrated relevant (for instance our pilot work (for predicting stroke and/or AF (a cut-off of 15% is highly specific, 20% being the optimal cut-off). LA-strain (cut-off 20%) c…

This description comes directly from the study's public registry record.

Talk to the study team

Courpron Julie  ·  02 99 28 25 55  ·  dri@chu-rennes.fr

ganivet anne  ·  anne.ganivet@chu-rennes.fr

Always discuss trial participation with your own doctor first.

Locations (17)

CHU AngersAngers, FranceNot Yet Recruiting
CHU Bordeaux Haut-LevêqueBordeaux, FranceNot Yet Recruiting
CHU Brest - Hôpital La Cavale BlancheBrest, FranceNot Yet Recruiting
CHU CaenCaen, FranceNot Yet Recruiting
CHU Dijon - Hôpital François MitterrandDijon, FranceRecruiting
CHU Grenoble AlpesGrenoble, FranceNot Yet Recruiting
CHU LilleLille, FranceNot Yet Recruiting
APHM - Hôpital La TimoneMarseille, FranceNot Yet Recruiting
CHU de Nantes -Hôpital Nord LaennecNantes, FranceNot Yet Recruiting
AP-HP Höpital la Pitié-SalpétrièreParis, FranceNot Yet Recruiting
APHP Hopital Européen Georges PompidouParis, FranceNot Yet Recruiting
APHP, Hôpital LariboisièreParis, FranceNot Yet Recruiting

+ 5 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07202897